GeoVax Labs, Inc., a clinical-stage biotechnology company, announced that senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco from January 12 to 15, 2026. The company will review its 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026, including key clinical catalysts, regulatory milestones, and business development initiatives.
The presentation is significant as it provides transparency into the company's advancements across multiple critical health areas. GeoVax will discuss CM04S1, its next-generation COVID-19 vaccine, focusing on clinical status, translational data, and regulatory pathways for high-risk and immunocompromised populations. This addresses a persistent public health need, as current authorized vaccines may be insufficient for vulnerable groups like those with hematologic cancers. The company's COVID-19 vaccine is currently in three Phase 2 clinical trials, evaluating it as a primary vaccine for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a more robust booster for healthy individuals previously vaccinated with mRNA vaccines.
In oncology, GeoVax will highlight Gedeptin®, a novel oncolytic solid tumor gene-directed therapy. The company will present translational and clinical data supporting development in head and neck cancer and other high-value solid tumor indications. A multicenter Phase 1/2 clinical trial for advanced head and neck cancers has recently been completed, indicating progress toward potential new cancer treatments. Additionally, the company will discuss GEO-MVA, a vaccine targeting Mpox and smallpox, covering regulatory progress, clinical strategy, and potential registration pathways for civilian and biodefense use. Based on recent EMA regulatory guidance, GeoVax anticipates progressing directly to a Phase 3 clinical evaluation for this vaccine, omitting earlier trial phases, which could accelerate availability.
GeoVax will also detail advancements in its manufacturing platform, focusing on continuous cell-line manufacturing that enables scalable, resilient, and domestic vaccine production. This has implications for supply chain security and pandemic preparedness. Business development opportunities, including partnerships and collaborations to support pipeline advancement and long-term value creation, will be addressed. David Dodd, Chairman and CEO of GeoVax Labs, stated that the team has delivered meaningful clinical and operational progress, strengthened the strategic position, and advanced multiple programs toward key inflection points in 2026. The presentation will be webcast live and accessible through the Events & Presentations section of the company's website at https://www.geovax.com, with an archive available for replay for approximately one month. Management will host one-on-one investor and partner meetings throughout the conferences to discuss the diverse pipeline.
This news matters because it showcases GeoVax's progress in developing vaccines and therapies that could fill unmet medical needs, particularly for immunocompromised individuals and cancer patients. The implications include potential new treatment options, enhanced biodefense capabilities, and more resilient vaccine manufacturing. For investors and the healthcare industry, it highlights strategic priorities and clinical milestones that may influence future partnerships and regulatory approvals. The focus on high-risk populations and scalable production underscores the company's role in addressing global health challenges, making this update relevant for public health stakeholders and medical communities.
